Travere completes asset sale to Mirum for up to $445M; pro forma shows reduced continuing ops revenue

Travere Therapeutics, Inc.

Net cash proceeds of $210M at close plus up to $235M in milestones from sale of Chenodal/Cholbam to Mirum; estimated gain of $235M.
Pro forma continuing ops revenue for H1 2023: $63M (down from $116.7M), net loss $198.6M, EPS ($2.75).
Pro forma continuing ops revenue for FY2022: $109.5M (down from $212M), net loss $329.8M, EPS ($5.17).
Pro forma balance sheet at June 30, 2023: cash $277M, total assets $897M, equity $348M.
Milestone payments of up to $235M tied to annual net sales thresholds of $125M-$500M for divested products.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.